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ABSTRACT OF THESIS 
RAPID NO• MEASURES IN RAT NUCLEUS ACCUMBENS AND FRONTAL 
CORTEX FOLLOWING NASAL ADMINISTRATION OF NITROGLYCERIN 
Nitric Oxide (NO) is a powerful endogenous free radical that has numerous 
biological functions including vasodilation and serves as a post synaptic second 
messenger in the central nervous system (CNS). Numerous studies implicate NO• 
involvement in CNS disorders such as schizophrenia and drug abuse. These studies 
address the direct in vivo determination of an FDA-approved NO• donor (nitroglycerin) 
on extracellular levels of NO• in the frontal cortex and core of the nucleus accumbens in 
a lightly anesthetized rat. State-of-the-art in vivo amperometric recording techniques 
coupled with a novel 4-channel low noise pre-amplifier system and new generation 
microelectrode arrays (MEAs) will be used to record extracellular levels of NO• at 100Hz 
before and during nasal administration of either placebo (1) or nitroglycerin. This studies 
will determine the feasibility of measuring NO• in the CNS while administering the NO• 
donor nasally and determine the amplitude and kinetic time course effects of a nasally 
delivered NO• donor in two rat brain areas, the frontal cortex and core of the nucleus 
accumbens. 
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Chapter One: Introduction and Outline 
Nitric oxide 
Nitric oxide (NO•) was recognized as a messenger molecule and chemically identical to 
endothelium derived relaxing factor (EDRF) in 1988 (Tassorelli et al., 1999)(Garthwaite et al., 
1988). This substance was known to cause vasodilation in the vasculature but the structure was 
unknown until 1988. Substances that act as nitric oxide donors, such as nitroglycerin and 
molsidomine, have been utilized to treat angina pectoris and myocardial infarctions due to these 
drugs abilities to lower blood pressure by relaxing blood vessels, allowing them to expand. Since 
then, nitric oxide’s cellular pathways, physiological roles and pathological associations in the 
brain have been elucidated. NO• has been implicated in disorders such as schizophrenia 
(Bernstein et al., 2005), drug addiction (Herman, 1995), and cancer (Choudhari et al., 2013). 
While further research is necessary to fully understand the role of NO• in these disorders, the role 
of nitric oxide in excitotoxicity, long term potentiation (LTP) and synaptic plasticity is well 
understood (Hardingham et al., 2013). One of the most well understood roles of NO• is in long-
term potentiation (LTP) and synaptic plasticity. This occurs via the activation of NMDA channels 
and postysnapic influx of Ca2+ that increases production of NO• (Hardingham et al., 2013). NO• 
then acts as a retrograde secondary messenger and strengthen the synapse, which is the cellular 
basis of learning. 
Nitric oxide is unique as a transmitter in the CNS in that it is membrane-permeable and 
cannot be sequestered in synaptic vesicles or spatially constrained by the synaptic cleft, as it can 
rapidly diffuse away from its source site across cell membranes (Tassorelli et al. 1999). For this 
reason it is not considered to be a neurotransmitter under the classical definition that restricts 
neurotransmitters to chemical substances that are generated in advance, stored in synaptic 
vesicles and, when released, diffuse and bind post-synaptically. The half-life of nitric oxide, in 
vivo, was found to be on the order of half a second, which is relatively short when compared to 
the traditional neurotransmitter dopamine, that has a half life of 2 minutes (Santos et al., 2011). 
However, there are still thought to be two modes of transmission that NO• takes part in; local  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signaling, in the retrograde direction, and volume-type transmission wherein multiple 
synchronous sources summate spatially (Garthwaite, 2018). 
Synthesis and signaling 
One way in which NO• is synthesized in the brain is by neuronal nitric oxide synthase 
(nNOS) via increase in intracellular calcium (Ca2+) that follows the activation of N-methyl-D-
aspartate (NMDA) receptors (Santos et al., 2011).  Glutamate, an excitatory neurotransmitter, 
binds to and activates NMDA receptors to cause a localized increase in calcium through the 
opening of calcium ion channels. Neuronal NOS is a calcium dependent enzyme and synthesizes 
NO• from L-arginine (Garthwaite, 2018). While nNOS and epithelial derived nitric oxide 
synthase (eNOS) are dependent on calcium for activation, inducible nitric oxide synthase (iNOS) 
is not. Ca2+ has such an affinity for iNOS that its activity is not modulated by calcium signaling 
but rather is mediated by cytokines (Hardingham et al., 2013). Additionally, the three types of 
NOS isoforms are found in different areas of the brain. nNOS has been found in 1-2% of neurons 
while eNOS has been localized to endothelial cells in the vasculature and to a small portion of 
neurons in the hippocampus. Finally, iNOS has not been found to be expressed in the healthy 
brain but has been seen in microglia and astrocytes following brain injury (Tassorelli et al., 1998). 
It is important to note that there is no consistent pattern of expression of NOS in terms of being 
localized to excitatory over inhibitory neurons. However, in some regions of the brain, such as the 
cerbellum, nNOS is found in a majority of the cells (Garthwaite, 2018). 
Nitric oxide’s mechanisms of action is known to be mediated through soluble gaunylyl 
cyclase (sGC). SGC, a heterodimeric enzyme consisting of one alpha and one beta subunit, is the 
most sensitive receptor of NO• (Hardingham et al., 2013). Two isoforms of alpha subunit exist 
and have differing regional expression. For example the alpha1/beta1 heteromer is dominate in 
the caudate-putamen and nucleus accumbens, a nucleus of interest in this study. The mechanism 
of action of activation of sGC by NO• is mediated by conformational changes via the binding at 
the heme site which enables sGC to convert GTP to cGMP (Hardingham et al., 2013). The 
receptor does this with incredible 10,000 fold selectivity of NO• over O2, despite the two 
molecules having similar anatomical structures. cGMP is then able to effect cGMP-activated  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protein kinases such as protein kinase G (PKG), initiating further downstream signaling events 
including phosphorylation of effector proteins (Hardingham et al., 2013). A depiction of the 
signaling pathways for NO• is found in FIGURE 1.2. Its important to note that signaling 
mechanisms may be tissue specific and are not fully understood. Factors such as nNOS 
concentration and local tissue media likely play a large role in the tissue specific role of nitric 
oxide (Garthwaite, 2018), (Santos et al., 2011). 
Decay and removal 
The half-life of NO• in Wistar rats, via carbon-fiber microelectrodes and ceramic-based 
microelectrode arrays, was determined to be 0.42 to 0.75 seconds (Santos et al., 2011). The ways 
in which NO• consumption impose this short half-life remains unclear. While several enzymes 
may contribute to NO• consumption in the brain, such as oxygen, cytochrome c oxidase, 
superoxide radical and cytochrome-P450 oxidoreducatse, the full mechanism of CNS NO• 
inactivation remains uncertain (Santos et al., 2011).  
Through the understanding that nitric oxide follows an apparent first-order decay rate, 
Santos et al. was able to study the role of red blood cells in NO• consumption through inducing 
hemorrhagic shock in wistar rats. One hour of progressive blood withdrawal resulted in cardiac 
arrest. During the hemorrhage, k, the first-order decay rate constant, was found to decrease. The 
average decrease was 53+/-4.6%, which was twice the decrease seen in anoxia conditions. These 
results suggest that circulating RBCs have a major role in governing nitric oxide dynamics in the 
brain and likely act as the largest NO• sink in the vasculature. This study additionally reported on 
the role of the vasculature in a neuroprotective  auto regulatory loop whereby local ischemia 
causes an increased concentration of NO•, which causes vasodilation which would decrease 
ischemia and reduce the level of NO• that, in high concentrations, can be neurotoxic. 
Scavenging of NO• by erythrocytes suggest NO• can easily diffuse through the vascular 
wall (Santos et al., 2011). NO• small size and hydrophobic nature has supported the notion that 
NO• diffuse freely in tissues. (Lancaster, 1997). While most molecules are retained in 
extracellular space due to tortuosity, Santos et al. 2011 found that nitric oxide is not constrained 
in the extracellular matrix in the same way most CNS signaling molecules are. Electrode  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recordings in agarose gel and in vivo in the rat brain found that NO• has a fast diffusion 
coefficient of 2.2 x 10-5 cm2/s and additionally suggested a role of cell membranes and 
hydrophobic structures as facilitating NO• diffusion.  
The mechanism in which NO• is cleared by RBCs is well understood through the binding 
of NO• to deoxygenated hemoglobin (Gow et al., 1999). NO• acts to nitrosylate hemoglobin 
thiols or react with free superoxide molecules in solution. The enzyme superoxide dismutatse 
(SOD) acts to eliminate superoxide in RBCs, increasing the concentration of S-
nitrosohemoglobin and nitrosylated hemes. SOD concentration is therefore able to regulate the 
production of nitrosylated hemoglobin thiols. This pathway of NO• inactivation allows RBCs and 
hemoglobin to act as a main regulator of NO• levels in vivo (Gow et al., 1999).  
Nitroglycerin 
Nitroglycerin, as depicted in FIGURE 1.1, has been utilized to treat angina pectoris and 
myocardial infarctions since the 1970’s due to its vasodilating effects. Vasodilation leads to 
increased coronary blood flow and reduction in cardiac pre- and post loads, treating the 
aforementioned disorders. Nitroglycerin acts via the formation of the reactive intermediate nitric 
oxide, who's cellular effect is described in the section titled “Nitric Oxide”. Nitroglycerin is 
small, non-polar and highly lipophilic and, consequently, should have good permeability of the 
blood brain barrier (BBB) to enter the CNS. While the complete mechanisms in which 
nitroglycerin is converted to NO• in the brain are unknown, it is understood that the enzymes 
glutatione-S-transferase and cytochrome P450, which are involved in biotransformation of 
organic nitrates, are responsible for synthesis of NO• in the brain parenchyma (Tassorelli et al., 
1999). Studies have demonstrated that nitroglycerin is biotransformed mainly by sulphydryl-
dependent enzymatic processes but can additionally be synthesized by sulphydryl-dependent non-
enzymatic processes. Interestingly, application of nitroglycerin onto brain nuclei causes an 
increase in the neuronal discharge rate. While, neurologically, nitroglycerin has been 
demonstrated to induce migraines, it shows promise as a nitric oxide supplement to potentially 
benefit disorders such as as drug addiction and schizophrenia. Additionally, nitroglycerin has  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already been FDA approved, minimizing the amount of time and financial resources that drug 
researchers have to put forward in order to yield potential new medications. 
Frontal Cortex 
The frontal cortex has been implicated in many functional roles within the brain such as 
decision making, language skills, emotion cognition and general consciousness (Teffer, 2012). 
The frontal region of mammalian brains is functionally unique in that it is not defined by a 
predominate input from any sensory system. Other cortical regions such as the occipital lobe and 
parietal lobe can be attributed to sensory input of vision and proprioception, respectively (Klob, 
1984). The frontal cortex has been associated with conditions like schizophrenia and drug 
addiction through the mesocortical pathway (Ekhtiari & Paulus, 2016). This pathway is a tract of 
dopaminergic neurons that connects the ventral tegmental area (VTA) with the pre-frontal cortex 
(PFC). This pathway is highly associated with cognition and executive function. Increased 
activation of this pathway is associated in drug addiction (Ekhtiari & Paulus, 2016). Conversely, 
dysfunction of this pathway has been found to be implicated in the negative symptoms of 
schizophrenia. Interestingly NO• has been implicated in pathologies of the frontal cortex through 
studies such as Reif et al., 2006. This study found that a functional SNP in the promoter region of 
nNOS is associated with schizophrenia and a worse frontal brain function. 
Animal models, especially the use of rats, for research into frontal cortex injury and 
function have been widely accepted in the research community. Despite large differences in the 
relative volume of the frontal cortex across species of mammals, there appears to be a largely 
conserved functions of the region (Kolb, 1984). This conservation of function is seen through 
studies that found both lesion and insult to the prefrontal cortex of both primates and rodents 
yielded similar sets of symptoms. These symptoms include poor performance on spatial learning 
tasks, reduced facial expression and impaired performance on tasks requiring changes in behavior 
(Kolb, 1984). These functional similarities suggest sufficient levels of translatability from rat 
studies to humans to support rat models of frontal cortex research. 
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Nucleus Accumbens 
The nucleus accumbens (NAc) has long been dubbed the “pleasure center” of the brain. 
This nucleus was first recognized as anatomically distinct from the more dorsal striatum by 
Lennard Heimer in 1975. The role of the NAc has since been further elucidated and it is better 
understood as a nucleus that aids in obtaining and directing attention towards motivationally 
relevant goals by promoting behaviors that increase the likelihood of obtaining rewards (Floresco, 
2015). The NAc is highly connected to other subcentral structures. It received inputs from the 
prefrontal cortex, basolateral amygdala, hippocampus and VTA. Outputs of the NAc include the 
ventral pallidum, hypothalamus and midbrain (Floresco, 2015). This strong interconnectedness 
allows the region to integrate many different inputs to direct behavior towards attaining potential 
rewards. 
The NAc has been associated with pathologies such as schizophrenia and drug addiction 
through the mesolimbic pathway. The mesolimbic pathway is a tract of dopaminergic neurons 
that connects the ventral segmental area with the nucleus accumbens (Ritz & Kuhar, 1993). This 
pathway is highly associated with human motivation, emotion and reward and its dysfunction is 
associated with the positive symptoms of schizophrenia and drug addiction (Floresco, 2015). 
Drug abuse is thought to cause increased dopamine neurotransmission in the mesolimbic 
pathway, which reinforces the behavior of drug administration and contributes to the addictive 
properties of many drugs (Ritz & Kuhar, 1993). Additionally, the nucleus accumbens, along with 
other structures within the striatum, has been found to have some of the highest concentrations of 
nNOS in the human brain and, consequently, is an area of intense interest in NO• research and 
pathologies (Bernstein et al., 2005). 
Intranasal Drug Administration 
Nasal administration of drugs was perviously reserved only for local treatment of 
disorders such as nasal allergy, nasal congestion and infections. Although the effect of nasally 
administered drugs on the CNS has been recognized since before the cocaine boom of the 1980’s, 
it wasn't until more recently that pharmaceutical drug companies have developed nasally 
administered to treat CNS disorders. Examples include the use of intranasal (IN) morphine and  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ketamine, to treat pain, and apomorphine to treat erectile dysfunction. This route of 
administration is expanding due to the limitation of off target effects and rapid onset (Illum, 
2003).  
Recently, drug development has branched into nasally administered vaccines, such as 
influenza and the treatment of neurodegenerative disorders like Alzheimer’s disease (Illum, 
2003). Through IN administration, researchers have reversed neurodegeneration and rescued 
memory in a transgenic mouse model of Alzheimer’s (Hanson & Frey, 2008). Additionally, IN 
insulin-like growth factor-I and erythropoietin have been shown to protect the brain against stroke 
in animal models (Hanson & Frey, 2008). Additionally, IN insulin has been shown to improve 
memory, attention and function in patients with Alzheimer’s disease without altering blood 
glucose (Hanson & Frey, 2008). Here, I will discuss the ways in which drugs administered via the 
nasal cavity are able to enter the CNS without crossing a selective filter such as the blood brain 
barrier, the pros of nasal administration and considerations for the use of IN drugs in animal 
models such as rats, which were utilized in this study. 
Intranasal (IN) drug delivery has been utilized to circumvent the blood brain barrier 
(BBB) that usually inhibits the transport of large, polar, hydrophilic molecules into the CNS 
(Hanson & Frey, 2008). The BBB, at the cellular level, is generally referred to as a neuro-vascular 
unit. This is comprised of endothelial cells of brain capillary walls, astrocyte end-feet that 
surround the capillaries and pericytes (Hanson & Frey, 2008). These cell structures help to block 
the import of unwanted compounds found in circulating blood through tight junctions, selective 
protein transporters and even cassette protein transporters that can export unwanted compounds 
once they have entered the CNS. 
Pros of IN administration over general systemic administration of compounds includes 
convenience, safety, cost and limitation of off-target effects. IN delivery limits the amount of the 
compound that enters the systemic circulation (Hanson & Frey, 2008). This minimizes off-target, 
possible negative side effects and the potential need to co-dose with peripheral inhibitors, as seen 
in the case of LDOPA and its peripheral inhibitor Carbidopa. An example is that of  IN 
administered insulin which does not significantly effect blood glucose levels, demonstrating a  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lack of off-target effects of IN administered drugs (Hanson & Frey, 2008). However, it is 
important to note that when drugs enter the nasal cavity, a portion still enters the blood stream and 
can affect tissues and organs, causing off target effects. A portion of the drug in the blood stream 
may be able to traverse into the CNS by penetrating the BBB. The percentage of compound that 
will successfully penetrate the BBB is dependent on the properties of the compound. Large 
molecular weight polar drugs such as peptides and proteins have relatively low permeability, 
generally no more than 1% for peptides and 10% for small polar drugs (Stenslik et al., 2015). 
Lipophilic drugs are generally well absorbed from the nasal cavity and boast bioavailability rates 
approaching 100%. One example of such a compound is IN fentanyl, that boasts an impressive 
bioavailability of ~80% (Illum, 2003). 
The olfactory nerve pathway has long been described as the main pathway to the CNS 
but recently the role of the trigeminal nerve in providing a direct connection with the CNS has 
been elucidated. Both nerves innervate the nasal cavity and consequently provide a direct 
connection to the CNS. A depiction of the innervation of the nasal cavity is seen in FIGURE 1.3. 
It is interesting to note that the trigeminal pathway has been associated with drug delivery to more 
caudal brain regions and the spinal cord when compared to the olfactory nerve pathway. For a 
drug to reach the CNS from the nasal cavity it has to transverse the nasal olfactory epithelium 
and, depending on the path taken, the brain’s arachnoid membrane (Illum, 2000). There are three 
suggested pathways that a drug can take to cross the olfactory epithelium, pictured in FIGURE 
1.4. First, the transcellular pathway utilizes receptor mediated endocytosis, fluid phase 
endocytosis or passive diffusion to allow drugs to cross the olfactory region’s cellular layer, 
specifically sustentacular cells (a type of support cell) (Illum, 2000). Next, paracellular transport 
is possible via tight junctions found between sustentacular cells and olfactory neurons. Finally, 
there is transport of compounds by the olfactory nerve pathway. In this mode the drug is taken up 
by a neuron via endocytosis or pinocytosis and then transported by axonal transport to the 
olfactory bulb. This pathway is thought to be relatively slow compared to the extracellular 
delivery pathways (Illum, 2000).  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There are many considerations to take into account with IN drug development. The nasal 
mucociliary clearance system has a half-life in the order of 15-20 minutes (Illum, 2003). This can 
decrease the absorption and bioavailability of the compound in the CNS, especially for drugs that 
are not easily absorbed across the nasal membrane (Illum, 2003). This issue can be resolved, in 
part, through the implantation of co-administered compounds that effect nasal absorption. These 
compounds, which include bile salts, work by either delaying the mucociliary clearance or 
increasing paracellular transport by opening the tight junctions between the epithelial cells (Illum, 
2003). Compounds such as starch and chitosan have been shown to slow mucociliary clearance 
and consequently increase the bioavailability of the drugs in the CNS (Illum, 2003).  
While no compound was co-administered in this study, the chemical properties of 
nitroglycerin, the nitric oxide donor utilized in this study, shape the compound as a potentially 
membrane permeable drug. Nitroglycerin has a relatively low molecular weight, is non-polar, and 
lipophilic, which is expected to enhance its ability to diffuse through sustentacular cells in the 
olfactory region of the nasal cavity (Tassorelli et al., 1999). A pro for the utilization of nasal 
administration of nitroglycerin is the potential limitation of off-target effect of peripheral 
vasodilation, which results in decreased blood pressure.  
It is important to take into consideration the species difference between humans and 
animal models of IN administration of drugs. The olfactory region of mouse, rat and non-human 
primate animal models cover a much larger proportion of the nasal cavity as compared to 
humans. Furthermore, in rat IN studies, the rat is commonly placed on its back during the study, 
which can increase the contact of the drug with the olfactory region. While this position was not 
used due to the MEA head-cap and FAST system attachment, the modified prone position that 
was utilized could potentially increase the amount of contact the test articles, nitroglycerin and 
miglyol, had with the olfactory region of the animal. These two considerations foster rat model 
studies as yielding more pronounced olfactory transport of drugs than in humans (Illum, 2000). 
Thesis Outline 
This study was utilized to determine the feasibility of measuring extracellular NO• in the 
CNS while administering a NO• donor, nitroglycerin, nasally and determining the amplitude and  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kinetic time course effects of a nasal delivered NO• donor in two rat brain areas, the frontal cortex 
and the nucleus accumbens. This section, Chapter One, covered the relevant background and 
current understanding of the synthesis, signaling and clearance of nitric oxide in the mammalian 
brain. Chapter Two will cover the use of microelectrode arrays (MEAs) as a measurement of 
nitric oxide in the extracellular space in two aforementioned subcortical structures. This includes 
a look into MEA fabrication, mPD exclusion layer coating and calibration carried out prior to 
electrode implementation. Chapter Three will delve into the experimental design, materials, 
surgical methods, experimental methods and statistical analysis used in this study. Finally, 
Chapter Four will cover the main findings of this study, considerations, and future directions. 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FIGURE 1.1: STRUCTURE OF NITROGLYCERIN 
Shown above is a depiction of nitroglycerin as seen in Tassorelli et al., 1999. It is easy to 
see how, when present in solution, nitroglycerin is non-polar with all three nitrate groups 
canceling each other out to leave a relatively non-polar compound free of large dipole 
interactions. This molecule is highly lipophilic and has a relatively low molecular weight. 
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FIGURE 1.2: NEURONAL SIGNALING PATHWAYS OF NITRIC OXIDE  
 Seen above is a schematic of the signaling pathway of nitric oxide as seen in Hardingham 
et al, 2013. This image depicts the signaling cascade from nNOS, shown here as NOS1, to the 
production of NO•, binding to sGC and production of cGMP that can cause multiple down stream 
effects. Not discussed in the corresponding section is the role of nitrosothiol groups in 
maintaining neuronal homeostasis and pre-synaptic plasticity.  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FIGURE 1.3: HUMAN NASAL CAVITY 
 The image above is depicted in Illum et al. 2000. This image depicts the olfactory bulb 
and its associated sensory neuron bundles that penetrate through the cribriform plate to the nasal 
cavity. This figure also depicts the high degree of innervation throughout the nasal cavity and 
facial region. This betters the visual understanding of the role that trigeminal nerve plays in nasal 
drug delivery alongside the olfactory nerve. It is also helpful to note the proportion of the nasal 
cavity that the olfactory region (below the olfactory bulb) occupies, as this is discussed in the 
considerations section of “Intranasal Drug Administration”.  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FIGURE 1.4: OLFACTORY NERVE AND OLFACTORY REGION CELL TYPES 
 Depicted are the various types of cells that support the olfactory region of the nasal 
cavity. Support cells, seen here as sustaining cells, are an integral part of the transcellular and 
paracellular pathways of IN drug uptake. Olfactory receptor cells are bipolar neurons which are 
seen here as “olfactory cell”. These cells give rise to a single non-myelinated axon which forms 
large bundles with other olfactory cells and penetrate through the basal membrane and, 
subsequently, through the holes in the cribriform plate. These fibers then synapse in the 
glomeruli, which reside near the surface of the olfactory bulb (Illum et al., 2000).  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Chapter Two: MEA Electrochemistry, Fabrication and Calibration 
MEA Fabrication 
Enzyme-based multisite microelectrode arrays are mass fabricated using 
photolithographic methods. This allows for mass production of reproducible recording surfaces as 
small as 5-10 µm (Hascup et al. 2006). A 2.5 cm x 2.5 cm x 125 µm thick ceramic wafer serves as 
a common substrate for the MEAS. Ceramic is used since it reduces the cross-talk from adjacent 
connecting lines and is strong and rigid (Hascup et al. 2007). Thin Films Technology, Inc., 
(Buellton, California) was the manufacturer of the four channel MEAs utilized in this study. 
Copper wires are soldered onto the paddle, one for each corresponding platinum (PT) recording 
site. Gold sockets are soldered to the other ends of the copper wire, which are inserted into a 
miniature black connector along with a miniature silver/silver chloride wire. Five-minute epoxy is 
applied to hold the apparatus together and keep the ceramic tip of the MEA parallel to the 
miniature black connector for stereotaxic placement. At this point, the entire apparatus is now 
referred to a pedestal MEA (Hascup et al. 2007). The MEAs were delivered to the Gerhardt lab 
pre-fabricated, only requiring reference electrode coating, mPD coating and calibration prior to 
being utilized in the study. An image of an MEA pedestal and rendering of the electrode tip can 
be found in FIGURE 2.1. 
Solutions Used 
Solutions used includes 0.05 M Phosphate Buffered Saline solution (PBS lite). The pH of 
the solution was tested and determined to be a desired 7.4.5mM. m-Phenylenediamine (mw 181.1  
Aldrich Chemistry) was made fresh daily due to the solutions tendency to oxidize within a few 
hours of synthesis. Additionally, 20 mM sodium nitrate solution and 8.8 mM hydrogen peroxide, 
2.0 mM dopamine were used. 
diethylenetriamine (DETA)/ nitric oxide adduct 
A 20 mM solution of DETA was utilized. This solution takes at least an hour to generate a 
stable concentration of NO• so the solution was allowed to sit for the minimum amount of time to 
generate a final NO• concentration of 0.2 mM before being used in a calibration experiment. 
5 mM m-Phenylenediamine  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5mM m-Phenylenediamine (mw 181.1  Aldrich Chemistry) was made fresh daily due to 
the solutions tendency to oxidize quickly (within a few hours of synthesis). First, nitrogen gas 
was bubbled through 100 mL of 0.05 M PBS solution for no less than 20 minutes. See PBS lite 
solution recipe above. Then 0.0905 grams of mPD (Sigma-Aldrich) was added to the 100 mL of 
PBS. This solution was inverted in the volumetric flask three times to mix. Solution was 
temporarily stored with paraffin film (Parafilm) until used to coat the MEA electrodes.  
mPD Coating 
5mM m-Phenylenediamine was made fresh daily as detailed in the “Solutions Used” section. A 
glass reference Ag/AgCl electrode, that is reserved just for plating, was placed in the beaker and 
attached to the Quanteon 20pA/mV headstage (Quanteon, Lexington, KY). The MEA was then 
attached to the headstage using the connector and the tip of the electrode was submerged in the 
mPD solution. Electroplater software was used (Quanteon, Lexington, KY). The P-P amplitude 
was set to 0.25, the offset was set to -0.5. Frequency was set to 0.05 Hz. This resulted in a wave 
pattern that generated three triangular waves per second. The Electroplater system was allowed to 
run for 15 minutes to sufficiently coat the electrode in mPD. The same electrode system was run 
in reverse chronoamperometry via the FAST system (Quanteon, Lexington, KY). The system was 
set to run at -0.55V vs. Ag/AgCl. This reverse current was utilized to partially remove some of 
the accumulated mPD. This process has been found to not negatively effect the role of the 
exclusion layer but simply boost nitric oxide selectivity (Friedemann et al., 1996). The mPD 
solution was exchanged for PBS and allowed to run for 5 minutes. After the completion of this 
reverse current, the MEA was removed from the headstage apparatus and stored at room 
temperature in a covered, light-proof container. 
Ag/AgCl Reference Coating 
While larger glass Ag/AgCl reference electrodes are suitable for mPD 
electropolymerization and microelectrode calibration, this reference electrode is too large for 
many biological applications. For this reason, a smaller Ag/AgCl reference electrode is fabricated 
and adhered to the head-cap of the MEA. In this section I will describe the process of coating this 
Ag wire with chloride (Cl). First, the ends of the silver wire were stripped of Teflon coating. The  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head cap was then placed into a clamp and the exposed end of the wire was placed into a 1 M 
HCl saturated with NaCl. A Pt  wire acts as the counter electrode and was also placed into the 
solution, not touching the silver reference electrode wire. Alligator clips, that were powered by a 
9V DC adapter, were attached to the electrode head-cap and the end of the platinum wire. The 
applied potential then attracted Cl- ions to the silver wire to form AgCl, thus yielding the Ag/
AgCl reference electrode. This phenomena was observed as reactive bubbling on the surface of 
the Pt wire. Current was sustained until there was an absence of new bubble formation, which 
signaled the end of the reaction. This generally took less than one minute in time. A depiction of 
reference electrode coating is seen in FIGURE 2.2. 
Calibration 
Calibration is utilized to test substance selectivity and normalize the coated sites for self-
referencing recordings. Using the FAST recording system, a nitric oxide donor (DETA) was the 
analyte of interest. MPD coating on the MEA, the exclusion layer, worked to select against 
measuring nitrate by physically blocking it from interacting with any of the four channels. 
Sodium nitrate was utilized as the interferent. Hydrogen peroxide (H2O2) was utilized as the 
positive control and displayed the sensitivity of the MEA. The analyte concentration was 0.2 µM 
and the interferent concentration was 250 µM. Recordings took place at 0.6V vs. Ag/AgCl 
applied voltage and recordings were measured at 100Hz. P200s and P1000s (Rainin 
micropipette), and corresponding 200mL and 1000mL pipette tips, were used during calibration 
as well as later during experimentation. Four compounds — an interferent (nitrate), analyte 
(nitiric oxide) and two test substances (DA and H2O2) — were applied to the PBS solution 
throughout the course of the calibration. A table of the order and volume of added solutions can 
be found in TABLE 2.1. All solutions were stored in a refrigerator at 5 degrees celsius. 
A 50 milliliter glass beaker was filled with 40 mL of 0.05 M PBS solution. This beaker 
was placed in a plastic holder which rested upon a battery operated, portable magnetic stir plate 
(Cole and Parmer portable magnetic stirrer). A battery operated stir plate was used to reduce 
potential AC (60Hz) current that can affect the recordings. A magnetic stir bar was added to the 
PBS solution and was set to stir slowly to avoid the formation of a vortex in the solution. A glass  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Ag/AgCl reference electrode is placed in the buffer solution. The microelectrode was attached to 
a 2pA/mV Quanteon headstage. The end of the Ag/AgCl reference wire is also plugged into the 
headstage. Finally, the microelectrode tip was partially lowered into the PBS solution 
(approximately a few millimeters). A photograph of the calibration system can be seen in 
FIGURE 2.4. After initial system settings were established on the FAST software, the recording 
system applied a potential of +0.6 V versus the Ag/AgCl reference to the microelectrode 
recording surfaces. The current was allowed to reach a stable baseline. This generally took 
anywhere from 10-15 minutes time. Once the baseline was achieved, it was ‘marked’ on the 
FAST computer system. 
 Following the establishment of a baseline voltage, 500 µl of nitrate was added for a final 
beaker concentration of 250 µM. When a new stable baseline was reached, the interferent was 
marked by the user. Next, three 40µl additions of 40 µM nitric oxide were added for final buffer 
concentrations of 40, 80 and 120 µl nitric oxide for a final concentration of 0.2 µM. Analyte 
marks were recorded after each addition to create the calibration curve. Following these three 
additions of analyte, 40 µl of 2 mM DA (2 mM, final beaker concentration) was added to the 
solution as a test substance and marked. Finally, 40 µl of 8.8 mM hydrogen peroxide was added 
to the solution to confirm microelectrode sensitivity and the addition was allowed to reach a new 
stable baseline and marked. A figure of the desired recording is found in FIGURE 2.5. After 
marking the second test substance baseline, the calibration was ended and resultant selectivity and 
sensitivity were analyzed. The MEA was removed from the apparatus and was stored at room 
temperature. The PBS solution that contained all four experimental solutions was discarded prior 
to starting another calibration. 
 Dopamine was utilized to further insure the integrity of the electrode and peroxide was 
used to examine the MEA over all responsiveness. The additions of test substances did not factor 
into calculating the standard curve for the analyte of interest since they followed the application 
of analyte. Chemicals used in vivo should be tested in vitro to ensure that they are not 
electrochemically active in vitro prior to its local application near the Pt recording sites during  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experimentation. This ensures that in vitro or in vivo analyte concentration changes are from the 
analyte of interest rather than due to local application of drugs. 
The calculations for selectivity ratios for nitric oxide over sodium nitrate, slope 
(microelectrode sensitivity for nitric oxide), limit of detection (LOD) and linearity (R2) are found 
below. A poor linearity, calculated by R2 is rarely seen with good microelectrodes. Since the 
microelectrode array fabrication procedure is highly reproducible, nitric oxide responses are 
extremely linear and resulted in linear regression curve fits with R2 greater than or equal to 0.99. 
Sensitivity of the microelectrode refers to how well the electrode can measure the change in nitric 
oxide. The sensitivity is calculated by the slope of the three additions of nitric oxide. This number 
is used to equate a change in current to a change in nitric oxide concentration. The slope is also 
utilized to calculate limits of detection which we have designated as the most important criteria 
for determining if a microelectrode is satisfactory for use. We utilize limits of detection (LOD) to 
select microelectrodes because slopes can be misleading. LOD refers to the limit of detection for 
the microelectrodes defined as the analyte concentration that yields an electrode response that is 
equivalent to three times the background noise of the recording system. This is calculated by 
taking the root mean squared of the background signal multiplied by 3 then divided by the slope 
((RMS background signal X 3)/slope of NO• signal). This is the lowest detectable change in 
analyte concentration that can not be attributed to noise, in other words the lowest detectable 
change that is significant. Microelectrodes with LODs that are lower than the response they 
expect to observe were selected. This is generally less than or equal to 1uM. 
Selectivity refers to a ratio of the microelectrodes sensitivity to nitric oxide over 
interferents such as nitrate. It is calculated by dividing the nitric oxide slope by the nitrate slope. 
The slope of the interferent is simply one point, the single addition of nitrate as compared to the 
baseline signal, but this has been found to be sufficient for selectivity calculations. A 
microelectrode with a selectivity of 100:1 means that for every 100 molecules measured 99 are 
nitric oxide while only 1 is nitrate. A selectivity of 100:1 ensures that the microelectrode is 99% 
effective at blocking nitrate. Selectivity ratios of 100:1 or greater were ideal. 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FIGURE 2.1: MEA SIZE AND DESIGN 
Above is an image of the microelectrode array used in this study. Ceramic-based MEAs 
were assembled and prepared by Thin Films Technology, INC., (Buellton, California). In this 
image, the MEA is compared to a standard metric ruler shown in centimeters. The red arrow 
indicates the tip of the MEA that contains the four channel electrodes. The Ag/AgCl reference 
wire is seen extending to the 5 cm mark below the ceramic electrode tip. It is possible to see the 
whitened tip of the reference electrode that has undergone the reaction with HCl to yield a white 
Ag/AgCl coating on the end of the wire. An image of the four channels is shown to the right. 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FIGURE 2.2: MPD AS AN EXCLUSION LAYER 
MPD was utilized as an exclusion layer for the detection of dopamine in vivo. This image 
shows the selective exclusion of compounds such as DA and NO3- , substances that could skew 
the accurate recording of NO• in vivo. Note that NO• and H2O2 are able to cross the mPD 
exclusion layer, reduce and donate one and two electrons, respectively, to the positively charged 
platinum (PT) sensor. The following balanced electrochemical reaction of the reduction of NO• 
on a metal surface, such as Pt, at a positive electrode potential. This reaction demonstrates that 
the oxidation of NO• in this experiment proceeds via a three-electron oxidation mechanism 
(Privett et al., 2010). A simplified equation is as follows: NO• + OH + H2O —> NO3- + 3e- + 3H 
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NO• —> NO+ + e- 
NO+ + OH —> HNO2 










PT        mPD
e-
e-
+ OH + H2O
N 3- + 3H
FIGURE 2.3: Ag/AgCl REFERENCE ELECTRODE COATING 
Depicted is a beaker of 1 M HCL saturated with NaCl, the MEA electrode being held by a metal 
three-prong clamp (indicated by the red arrow, left) and a platinum (Pt) wire (indicated by the 
blue arrow, right). The MEA and Pt wire were attached to a 9V DC adapter fitted with alligator 
clips that were hooked to electrical wires as depicted. The reaction was run to yield an Ag/AgCl 
reference wire Once the reaction was run to completion and NO• further bubbling was observed 
on the Ag reference wire, the current was cut off. After coating, the ends of the silver wire were 
observed against a high-contrast black background to ensure that a bright, white Ag/AgCl 
reference wire was produced. MEAs were then returned to dark storage in boxes and were stored 
at room temperature. 
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TABLE 2.1: CALIBRATION SOLUTIONS 
This table depicts the order and volume of the solutions added throughout the course of electrode 
calibration. All agents were added after a baseline was established and “marked” on the FAST 
system. The first additive, nitrate, was added following a 15 minute stabilization period that 





Solution number of 
additions
1 Interferent 500mL/250uM Nitrate 1
2 Analyte 40mL/6.2uM Nitric Oxide 3
3 Test substance 40mL DA 1
4 Test substance 40mL H2O2 1
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FIGURE 2.4: CALIBRATION SET-UP 
Depicted above is the complete set-up of a calibration experiment. The plastic stand sits atop the 
battery powered magnetic stir platform. A 50mL beakers placed in the stand and filled with 40 
mL of PBS lite solution. A miniature stir bar was added to the beaker and was utilized to circulate 
the added calibration compounds. The MEA is shown attached to the Quanteon 2pA/mV 
headstage, shown left. The silver reference electrode is shown on the right of the beaker and was 
attached to the reference attachment point on the headstage. Not shown is the connection to the 
FAST system, displayed on a desktop computer or the test compounds utilized during a 
calibration.  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FIGURE 2.5: NITRIC OXIDE CALIBRATION GRAPH 
This image was adapted from Hascup et al. 2006. The additions follow the order and 
volume noted in TABLE 2.1. This graph depicts the desired current observed from the 
subsequent additions of analytes over time. Note the lack of response after the addition of  nitrate 
(denoted NO3-). This is followed by three 40ml additions of the nitric oxide solution (NO). The 
dashed line indicates the slope of the analyte addition, showing compounding activation with 
each addition. The sensitivity of the microelectrode is inferred by the slope of the three analyte 
additions. The graph shown here has strong linearity and correlation between subsequent 
additions and detection of NO. 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Chapter Three: Materials and Methods 
Animals 
A total of 10 (5 per brain region) research naïve male Wistar rats (F344) 1-2 months old 
weighing ~150-175 (Envigo) were needed for this study. Upon arrival at the University of 
Kentucky, individual cage-card and research chart were created and the animals were allowed to 
go through a standard acclimation/quarantine period while being housed in the DLAR facility. 
After the 7 days acclimation period animals were implanted with an electronic ID transponder.  
The Wistar rat was chosen as the test system because of its established usefulness and 
acceptance as a rat strain. It is also the phylogenetically lowest species that provides adequate 
size, tissue and anatomy for the proposed studies. The number of animals used is the minimum 
necessary to obtain scientifically valid results. The total number of animals used in this study was 
14, not 10, due to varied adverse outcomes that resulted in animals not completing the full three-
part experiment. The study does not unnecessarily duplicate any previous work and alternatives to 
the use of live animals have been considered. Procedures used in this study have been designed to 
avoid or minimize discomfort, distress or pain in the animals.  Animals that experienced severe 
chronic pain or distress that cannot be relieved would have been painlessly euthanized in 
consultation with the University of Kentucky veterinary staff and Study Director. The Study 
Sponsors would have been advised by the University of Kentucky in a timely manner of all 
circumstances that could have lead to this action.  
Experimental Design 
Two sets of in vivo electrochemical studies with 5 rats per arm (10 animals total) were 
carried out in order to evaluate the effects of nasal administration of NO• donor on extracellular 
NO• levels in 2 brain regions, the nucleus accumbens and frontal cortex. Each animal (n=10, 5 
per brain region) received 3 treatments.  
Due to the nature of these experiments and analyses, it was expected that the experiments 
be conducted for 3 weeks per animal (2 animals per week on study) with analyses performed on 
the data after completion. We estimated that the in-life of the recordings would span a total of 14 
weeks and final analyses, histology and data analyses would take an addition 4-6 weeks; total  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study in-life was estimated to be 24 weeks (6 months) including study start-up, which involves 
animal protocol approvals. The timeline was adjusted as study modifications were needed 
throughout the course of experimentation (when requested and approved by the study sponsor in 
consultation with the testing facility). All efforts were taken to maintain the study timeline, 
although secondary to any needed actions to maintain data quality and reproducibility. 
Randomization and Blinding 
Animals were randomly assigned into 2 groups (each brain region). Animals received 
placebo (negative control) and NO• donor (nitroglycerin at 2 different doses) and the test and 
control articles labeled A, B and C were administered via nasal administration such that Study 1 
and Study 2 had a total of 10 animals that received the 3 treatments. Test and control articles, 
although identified alphabetically A, B and C by label, are coded by the study director so that 
experiments and analyses are performed with study staff blinded to the test groups. All animals 
received all three treatments, following the randomization scheme depicted in TABLE 3.1. 
Test and Control Articles 
The sponsor provided the NG formulations. The Study Director transferred materials to 
vials and prepared the saline and SNP solutions daily. The Study Director provided the 3 solutions 
(blinded) labeled A, B and C to the PI on the day of use.  
Recipes: 
A) Negative control (Miglyol)
B) Nitroglycerin (NG) 50 mg/ml (dissolved in Miglyol); 15 mg/kg
C) Nitroglycerin (NG) 50 mg/ml (dissolved in Miglyol); 10 mg/kg
(Nitroglycerin solution dissolved in Miglyol, 50 mg/ml - Novasep) 
Test and control articles were stored as indicated by Novasep Synthesis.  
Any residual test and control articles were stored at 5 degrees C in a refrigerator until after the 
final report has been signed/approved by the study director in consultation with the study sponsor, 
at which time residual samples may be discarded. The weight of the animals, on average, was 
slightly higher than the originally anticipated maximum value of 400 grams. Animal weight 
during experimentation ranged from 366-454 grams. The concentration of the test article was  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adjusted accordingly by the study director to ensure the same volume of TA was delivered during 
experimentation. 
Nasal Administration 
The test and control articles were administered via nasal delivery with animals under 
isoflurane sedation, as described in Stenslik et al., 2015. Administration was via P200 
micropipette tips. Further information and considerations of intranasal administration can be 
found in the corresponding section. 
Controls  
Controls are intended to show the effect of procedure or experimental design in the 
absence of the agent of interest. In this study, the control was Miglyol. 
Husbandry and Veterinary care 
The procedures described in this section were performed in accordance with the 
appropriate standard operating procedures in use by the University of Kentucky Division of 
Laboratory Animal Resources (DLAR). The animals were given an acclimation period of 
approximately one week. All adverse consequences resulting from administration of the test 
article and collection procedures as well as subsequent treatments provided by a qualified 
member of the veterinary staff were documented in the study records. While adverse 
consequences are described in the section labeled, “Adverse Outcomes”, no subsequent 
treatments were provided by a member of the veterinary staff and consequently not recorded. 
Animal Housing 
All animals in the study were housed in the University of Kentucky DLAR facility, which 
is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC). While on study, the animals were housed in plastic boxes and maintained on a 
12-hour light/12-hour dark cycle in temperature-controlled and humidity-controlled rooms,
ranging approximately from 64˚F to 84˚F and 30% to 70%, respectively. Each housing unit was 
identified with a cage card indicating, but not limited to: animal ID number, species, sex, vendor 
and IACUC protocol number. A variety of toys were provided to the animals for enrichment. 
Dietary materials 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Each animal was fed a standard, commercial diet ad libitum. Municipal tap water, 
purified by reverse osmosis was available ad libitum via an automated watering system. 
Additionally, animals were provided supplemental snacks upon completion of each of the three 
parts of experimentation. This treat was either Cheeto cheese puffs or Pops sugar puff cereal. 
There were no contaminants suspected in either the diet or purified water that would be expected 
to have an effect upon the outcome of the study.  
Procedures 
Surgical Procedure 
Surgical procedures were carried out based on the University of Kentucky DLAR 
standards of aseptic anesthetized animal surgery. Pre-surgical procedures were as follow: 
Isoflurane (Attane Isofulurane, USP liquid for inhalation) was replenished in the 
vaporizer and a heated water pad (Gaymar Industries, Inc, TP3E), connected to a water 
bath (Gaymar Industries, Inc, T/Pump, TP500), was set to 40 degrees celsius to maintain 
an animal body temperature of 37 degrees celsius. Animals were sedated in an induction 
chamber at 3.0-3.5% Isoflurane. Animals were then transferred to a stereotaxic frame 
(Koph Instruments) and secured into place with a palate clip and ear bars. Both the 
induction chamber and stereotaxic frame received vaporized Isoflurane from a Patterson 
Veterinary Vaporizer. The palate clip of the stereotaxic frame was set at -2.3 cm and ear 
bars entered the ear canal and were set at an average of -7.0 to -8.0 cm on either side to 
secure the head in a flat plane. Anesthetic was reduced to 2.0-2.5% for the remainder of 
the surgery. Animals were administered Rymadyl (5mg/mL) at 5mg/kg to mitigate pain 
from surgery. The animals’ eyes were lubricated with lubricant eye ointment (Lubrifresh 
P.M (sterile) to prevent dry eyes or debris from entering their eyes. Animal heads were
shaved near the intended site of incision from between the eyes to past the approximate  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location of lambda. Betadine was then applied locally to the shaved area and two sterile 
alcohol prep pad wipes (Fisherbrand medium) followed to ensure a sterile site of incision.  
An inch long incision was made in between the eyes using a 10 blade scalpel 
(Feather Surgical Blade and Handle stainless steel) that was extended approximately an 
inch caudally. Fascia was removed from the top of the skull and stainless-steel clamps 
were used to secure the fascia away from the surgical field. Cautery was used as needed 
to limit bleeding. Additionally, 0.9% saline solution and gauze pads were used to clear 
the surgical field of blood and debris as needed throughout the procedure. Bregma was 
identified and marked using a permanent marker (Sharpie), helping divide the surgical 
field into four identifiable quadrants. Three burr holes were made using a Dremel 107 bit 
(2.4mm) on a Froedom MH-170 surgical drill. These three holes, intended for screws, 
were placed into all of the quadrants except for the right rostral quadrant, which was 
reserved for S2 electrode implantation. An additional burr hole was made in the quadrant 
diagonal from the electrode quadrant. This hole was utilized later for placement of the 
reference electrode. A diagram of the schematic of the burr holes as seen on a dorsal view 
of the rat skull can be found in FIGURE 1. Screws were removed from their storage in 
isopropyl alcohol, rinsed with 0.9% saline solution and then screwed into the three burr 
holes. A rat’s skull thickness can be anywhere from 0.5-1.0 mm (Paxino & Charles, 1998) 
and the screw threads were 2.0 mm. Once threaded, the screws were screwed in about 
1mm to leave approximately 1.0 mm exposed above the skull.  
The burr hole position for the electrode was approximated from bregma. The two 
subcortical areas of interest were measured as noted in TABLE 3.2 found in the supplemental  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images. All measurements were based on the atlas (Paxino & Charles, 1998) and were 
measured from the electrode tip, attached to the stereotaxic frame, from the center of 
bregma. Abbreviations for electrode implantation coordinates are Anterior-Posterior 
(AP), Medial-Lateral (ML), Dorsoventral (DV). Coordinates were for nucleus acuumbens 
were AP: -1.0, ML: -2.2, DV: +7.8 and AP: -3.2, ML -0.8 and DV: +5.5 for the frontal 
cortex. Forceps were used to ensure that the burr hole was smooth and perpendicular at 
all points, so the electrode would not touch any portion of the skull that was not clearly 
visible from the dorsal surface of the skull. The electrode was placed on the stereotaxic 
frame arm and the tip of the electrode was measured to a subcortical region from bregma 
using AP and ML measurements. Adjustments to the burr hole were made on an as-
needed basis. This includes removing the electrode from the surgical field, via moving 
the stereotaxic frame arm, to drill further to enlarge the burr hole.  
Once the electrode was aligned and deemed ready to be implanted, the Ag/AgCl 
reference electrode was placed into the reference burr hole. The electrode was implanted 
under the skull so that it sat parallel to the skull to minimize localized neuronal damage 
from the electrode implantation. The reference wire was then wrapped around the two 
posterior screws to secure it in place. The electrode was then implanted into the cortical 
area of interest. Electrode placements were confirmed post-mortem through cryostat 
brain sectioning (Gerhardt et al. 2018). Once the electrode was placed at the proper DV 
location, superglue and activator (Kwik-Fix project glue, Kwik-Fix activator) was applied 
to the electrode tip to secure the electrode into place. From this point, additional glue and 
activator was used to build a mound around the S2 apparatus. Clips were removed from  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the surrounding fascia and the skin surrounding the surgical field was adhered to the S2 
system.  
The animal was taken off anesthesia, removed from the stereotaxic frame and 
returned to its housing unit that was placed on a heating pad. The heating pad helped 
maintain the animal’s body temperature while regaining consciousness. Animals were 
monitored for three days post surgery. Daily weights were taken. Rymadyl was 
administered intramuscular daily in doses of 5 mg/kg. After this recovery period, animals 
were returned to the DLAR animal facility for housing for the next three weeks. Animals 
were run through the first study seven days after the surgical implantation date.  
Experimental Procedure 
Seven days after implantation of the MEA pedestals, rats were connected to a 
FAST Mark IV electrochemical recording system, which is controlled by a Labview/
Matlab software interface for real-time measures. Two animals were run simultaneously 
and always through the same computer and induction chamber throughout the course of 
the full experiment. Experiments were conducted no sooner than seven days following 
surgery and no sooner than five days following the previous experiment. This ensured 
sufficient amount of time for the animal to eliminate any test agents from their body 
(Gerhardt, Greg A, et al. 2018.). Experimentation took, on average, five hours. This time 
includes retrieving animals from the animal storage facility, induction and both rounds of 
test article administration. Experimentation had two sections. The first sections 
recordings took place at +0.6 V vs. Ag/AgCl. A baseline measure was recorded for 30 
minutes before the nasal administration of test articles. Recordings continued for an  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additional 1.5 hour. The recording were then reset to +0.2 V vs. Ag/AgCl and baseline 
was recorded for another 30 minutes. The designated test article was delivered by nasal 
delivery under sedation to determine possible noise and/or interference to the NO• 
signals. Recordings were continued for an additional 1.5 hours.  
Prior to experimentation, animals were first induced in an induction chamber at 
3.0-3.5% Isoflurane (Attane Isoflurane, USP liquid for inhalation). Once anesthetized, 
animals were weighed and attached to the head-stage of the Fast Analytical Sensing 
Technology (FAST) computer-controlled potentiostat system (FAST; Quanteon, 
Lexington, KY). The animals were positioned in a modified prone position with their 
heads angled upward towards the corner of the induction chamber to allow for easy nasal 
administration of the test articles. A depiction of this positioning is seen in FIGURE 3.2.  
Once properly positioned and deemed sufficiently sedated, Isoflurane levels were 
reduced to 2.0% for the remainder of the first 30 minute baseline recordings. Test articles 
were retrieved from storage at 5 degrees celsius. Test and control articles were all made 
by the study director within 48 hours of experimentation and blinded to the experimenter 
through designations article A, B and C (Gerhardt et al. 2018). After the 30 minutes of 
recording a baseline signal, the test or control articles were administered by micropipette 
tips (Rainin micropipette). 125 µl of test agent was administered over a 5 to 6 minute 
period. 12.5 µl was administered per nostril with one minute wait periods in between the 
end of each article administration. This means that 25 µl was administered five times 
over an average of six minutes. 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After nasal administration, recordings were continued for another 90 minutes 
under light sedation of 1.5-1.75% Isoflurane. Upon completion of the +0.6 V vs. Ag/
AgCl recording, animals were maintained under sedation and run through the same 
experimental procedures at +0.2 V vs. Ag/AgCl, which was repeated over the following 
two hours. This recording was utilized to administer the designated test or control article 
again to determine possible noise and/or interference to the NO• signals recording for the 
final 90 minutes of the two hour total recording time. At the end of experimentation, 
animals were removed from anesthesia and returned to their home cages. The cages were 
placed on a heating pad to help maintain a normal body temperature until regaining 
consciousness. Animals were then returned to the University of Kentucky DLAR facility 
for a five day (minimum) anesthesia washout period. The remaining 2 of the 3 articles 
were administered over the course of the next two weeks, one per week. Thus, animals 
received 3 treatments over the 15-21 day period (Gerhardt et al. 2018).  
Administration of test articles resulted in a variety of observable behaviors including 
change in respiration rate and depth. Often, following the second round of nasal administration, 
noticeable difficulty in breathing was observed. This was considered a potentially severe adverse 
outcome. Adverse outcomes are further documented in the corresponding subsection. 
Additionally, eye blink and reflexive head movements were observed during nasal administration 
in most animals. This was considered a consequential outcome from TA delivery and not an 
adverse outcome. Animals that displayed significant head jerk activity as a reflexive response to 
nasal administration of the test article were not repositioned to the modified prone position until 
at least 10 minutes following that round of nasal administration. This precaution was taken to 




At the completion of the testing of the 3 treatment recording days, rats were euthanized 
by Isoflurane sedation utilizing sustained level Isoflurane (4-5%) for up to five minutes until 
normal breathing was notably disrupted. Animals were subsequently decapitated, placed in a 
labeled bag and stored in a -18 degree freezer. Brains were removed later and sliced using a rat 
brain mold to confirm the location of the MEAs (Gerhardt et al. 2018). 
Adverse Outcomes 
Throughout the course of this experiment four animals did not finish experimentation 
and, consequently, new animals had to go through the acclimation period, surgery, recovery time 
and then run through the entire three part experiment. This group of animals includes three 
animals from the nucleus accumbens group and one animal from the frontal cortex arm of the 
study. The adverse outcomes included the loss of the animal’s head cap, generally caused by the 
animal’s own self mutilation by bumping its head, and death during experimentation. A more 
detailed list of fatal events are found in TABLE 3.3. The adverse event of head-caps falling off 
was determined to be caused by expired project glue (Kwik-Fix instant bond as well as adhesive). 
Following replacement of project glue with non-expired product, the issues of lost head-caps seen 
in animals #1 and #2 was not seen in any subsequent animals. The second fatal issue seen in 
Animals #5 and #9, death during experimentation, was determined to be due to poor circulation 
and aspiration of the test article during experimentation. After implementation of a heating pad 
for animal #8 (experiment 3) and animals #5 and #10, this issue of death due to insufficient 
respiration was not observed again. Animals that displayed severe respiratory disturbance 
following the second round of test article administration were moved to a full prone position to 
ease their breathing. This movement was made no sooner than 10 minutes following the end of 
the TA administration. 
Non-fatal adverse outcomes were also observed throughout the course of 
experimentation. Mild respiratory distress was the most prevalent and most concerning adverse 
event. Changes in breathing were closely monitored during and following nasal administration of 
the test article. Generally, significant changes in respiratory rate and depth were observed  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following the second round of nasal administration of the test article during the 0.6 V vs Ag/AgCl 
recording period. Other non-fatal adverse outcomes included, but were not limited to difficulty 
regaining consciousness post experimentation. This was defined as any time greater than 20 
minutes after being removed from anesthesia. This event was observed in <5 animals. 
Record Retention 
Modifications in the study design were only made with verbal or written consent of the 
Study Director. Verbal authorization must be documented in the raw data and followed by a 
written protocol amendment within 10 business days. All amendments or deviations to the 
approved study protocol were documented, signed by the Study Director, dated, and maintained 
with the study protocol . All amendments to the approved study protocol were also approved by 
the Sponsor. After the final report is approved by the Study Director, all raw data and specimens 
relating to this study will be archived for up to 1 year. The test facility archives staff will contact 
the Sponsor after 1 year following report finalization to determine disposition of the archived 
materials (except for the raw data on durable media, study correspondence, and the copy of the 
final report). Portions of the study conducted by the sponsor or sponsor’s designee will be 
archived in the storage facilities of the sponsor or sponsor’s designee (Gerhardt et al. 2018). 
Data Analysis 
All data sets were analyzed by our Matlab based analysis system that involves FFT 
filtering, boxcar averages and averaging of data from the 4 sites of the MEAs prior to averaging 
of responses from the different animals. The low voltage measures were used to identify any 
interferences. Our detection limits in vitro are estimated to be in the 10-20 nanomolar range 
(Santos et al. 2011). In vivo results can vary due to physiological changes that may occur at the 
higher doses of test article administration. The studies were based in groups of 5 due to power 
analysis requirements. Power calculations using an α=0.05, β=0.10, and a detectable difference of 
30-40% from baseline for the measures predict the necessary sample size of n=5 for the proposed
studies. All data were analyzed using an Analysis of Variance (ANOVA) followed by appropriate 
post-hoc comparisons. Final data analyses is focused on the effects of the 3 treatments on 
maximum extracellular NO• ([NO]max) and kinetic data of the signals involving Trise, T1/2, T100  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(all in minutes). Note: these are discovery studies with no guarantee that the doses and route of 
administration of the NO• test article would produce detectable levels of NO• (Gerhardt et al. 
2018). 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TABLE 3.1: RANDOMIZATION OF TREATMENT ORDER 
This table depicts the randomization of treatment groups. The randomization order was 
followed for both groups (the two brain regions). As noted in the corresponding section, test or 
control articles were all made by the study director within 48 hours of experimentation and 
blinded to the experimenter through designations of article A, B and C (Gerhardt et al. 2018). Test 
and control articles are described by composition and concentration in the section labeled test and 
control articles. The experimenter was blinded to which article corresponded to each compound. 
This ensured that the order of test article administration did not confound results. 
Treatment Day
Animal 1 2 3
1 A B C
2 B C A
3 A C B
4 B C A
5 A B C
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FIGURE 3.1: DORSAL SKULL VIEW 
Depicted in the image above is the view of a rat skull as seen in The Rat Brain: in 
Stereotaxic Coordinates by George Paxino and Charles Watson. This image has been modified 
from the original text to include color coded dots that indicate the approximate location of burr 
holes that were made during the S2 implementation surgery. Yellow dots indicate the locations of 
screws and the green dot indicates the location of the Ag/AgCl reference electrode. The Ag/AgCl 
reference electrode burr hole is placed in the contralateral quadrant to minimize any noise or 
electrical interference from the S2 electrode and provide the best possible reference signal. The 
red dot indicates the location of the S2 electrode burr hole for the nucleus accumbens and the blue 
dot indicates the location of the S2 electrode implantation burr hole for measuring local nitric 
oxide levels in the rat frontal cortex. Note: all burr hole placements shown are approximate. 
During surgical implantation of the MEA, the two different regions for electrode placement were 
measured using the stereotaxic arm. 
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TABLE 3.2: SUBCORTICAL COORDINATES 
Depicted above is a table of the A/P, M/L and D/V for the two subcortical areas of 
interest. All values are listed in millimeters. Subcortical locations were referenced based on 
(Paxino & Charles, 1998). These locations were measured using the stereotaxic frame (Koph 
Instruments) from bregma, as noted in (Paxino & Charles, 1998). The tip of the MEA was 
attached to the stereotaxic frame arm and placed directly above bregma and AP and ML 
measurements were made using this arm. Once the electrode was above the pre-drilled burr hole, 
the MEA was ensured to fit properly in the opening. If adjustments were necessary, the MEA on 
the arm was removed from the surgical field, necessary adjustments were made to the burr hole to 
ensure proper location of MEA placement. Then the MEA was again measured from bregma. DV 
was reset once the MEA tip came into contact with the dura. Once placement was correct, the 
process of applying the project glue and drying it with the Kwik-Fix activator was initiated. 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Nucleus Accumbens: 
AP     -1.0 
ML    -2.2 
DV    +7.8 
Frontal Cortex: 
AP     -3.2 
ML    -0.8 
DV    +5.5
TABLE 3.3: ADVERSE OUTCOMES LEADING TO PREMATURE 
EXPERIMENTATION TERMINATION 
Two adverse events resulted in premature death or euthanization. This included the loss 
of the animal’s head-cap, the top of the MEA that held the attachment points to the four channel 
electrode as well as anchored the reference electrode wire. In one case, the head-cap popped off 
from excess pressure experienced from the attachment to the FAST system. In the other case, the 
animal, through self mutilation, caused the release of the head-cap from the skull by breaking the 
adhesive. Both animals were euthanized following the loss of the head-cap. Two animals died 
during experimentation from what was dubbed respiratory distress due to aspiration of the test 
article. The test articles administered to animals #5 and #9 were B and C, respectively. Both of 
these test articles contained nitroglycerin, although in different concentrations, but the chemical 
properties of nitroglycerin, as compared to miglyol, could potentially account for this outcome. 
However, this issue was resolved and not observed again after the implementation of heating pads 
during experimentation. This was utilized to help normalize circulation and body temperature 
during the experimentation of these anesthetized animals. 
Animal number Number of 
experiments 
completed




Animal #1 1 lost head-cap second animal #1 
completed full 
experiment 
Animal #2 1 lost head-cap second animal #2 
completed full 
experiment 11/8/18
Animal #5 1 death during 
experiment 2 due to 
respiratory distress




Animal #9 1 death during 
experiment 2 due to 
respiratory distress





FIGURE 3.2: EXPERIMENTAL POSITIONING 
The animal position during experimentation is depicted in the image (viewed from below 
the animal). Animals were positioned in this modified prone position to allow for easy nasal 
administration through the nostrils due to being exposed and easily accessible by micropipette 
tips. Shown in dashes is the induction chamber that the animals were placed in during 
experimentation. This rectangular box allowed the animals to rest on their belly while their heads 
were placed at a sharp upward angle to facilitate the nasal administration of test articles. During 
experimentation, the animal rested both of its cheeks on either side of the corner of the induction 
chamber. 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Floor of induction chamber
Chapter Four: Results and Discussion 
Results 
In this study we used amperometric recording techniques coupled with a 4-channel low 
noise pre-amplifier system and new generation microelectrode arrays (MEAs) with high spatial 
(µm) and temporal (100 Hz) resolution to explore in vivo effects of an FDA-approved NO• donor 
(nitroglycerin) on extracellular levels of NO• in the frontal cortex and nucleus accumbens of 
lightly anesthetized Wistar rats following intranasal administration. FAST recording system was 
utilized to record the full four hour experiment. An example of a tracing produced from the 
experiment can be seen in FIGURE 4.1. 
Frontal Cortex 
The results of the frontal cortex, as seen in FIGURE 4.2, do not show any significant 
difference in measured extracellular NO• levels between the three treatment groups, myglol, 10 
mg/kg nitroglycerin (NG) and 15 mg/kg nitroglycerin. The average value of the area under the 
curve (AUC) was ~1,000, ~1,000 and ~1,000 for myglol, NG10mg/kg and NG 15mg/kg, 
respectively. While the 95% does include 0 for all compounds except the 15mg/kg Nitroglycerin 
dose, meaning the nasal administration of the other two compounds could, theoretically, not cause 
a localized extracellular increase in NO• in the frontal cortex at all, it is likely with increased 
sample size (N) that there would be significant difference from 0 for all three compounds. 
However, there is no significant difference between the increased extracellular concentration of  
NO• following nasal administration of  NG as compared to myglol.  
Nucleus Accumbens 
The results of the nucleus accumbens, as seen in FIGURE 4.3, do not show any 
significant difference in measured extracellular NO• levels between the three treatment groups, 
myglol,10 mg/kg nitroglycerin and 15 mg/kg nitroglycerin. The average value AUC was much 
higher than for the frontal cortex at ~4,000, ~5,000 and ~4,000 for myglol, NG10mg/kg and NG 
15mg/kg, respectively. While the 95% does include 0, meaning the nasal administration of all 
three compounds could not cause a change in extracellular NO• in the nucleus accumbens, it is 
likely with increased sample size (N) that there would be significant difference from 0 for all 
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three compounds. While there is no significant difference between the increased extracellular 
concentration of  NO• following nasal administration of  NG as compared to myglol, it is 
interesting to note that the average AUC values of all three test articles are approximately five 
times higher than those measured in the frontal cortex. 
Conclusions 
This study was unable to conclude there was a significant difference in the level of 
extracellular nitric oxide measured in the rat frontal cortex and nucleus accumbens following the 
nasal administration of nitroglycerin, a widely accepted nitric oxide donor, when compared to the 
placebo of Miglyol. It does suggest that nasal administration of myglol may cause a significant 
increase in extracellular nitric oxide in the two subcortical areas of interest. This could be due to a 
physiological response to nasal administration. This theory suggest that, regardless of the 
compound, nasally administered substances cause a response in animals that causes increased 
extracellular NO• in the two subcortical areas. A way to test this theory is to add an additional 
control of saline, as myglol itself has to be ruled out from causing the observed effect. 
There are many hypotheses as to why nitroglycerin did not significantly effect the 
extracellular concentration of NO•. Firstly, there is the chance that NG was not able to enter the 
CNS through the nasally administered drug route described in the section, “Intranasal drug 
administration”. While the chemical properties of nitroglycerin suggests the drug should be able 
to cross the sustentacular cells via receptor mediated endocytosis and enter the brain, 
nitroglycerin may not easy utilize this so called transcellular pathway. Additionally, the drug may 
not be able to enter the brain via transversing tight junctions of sustentacular cells in the 
paracellular pathway. It was already demonstrated in previous research that, despite following all 
of Lipinksi’s rules except for the number of H bond donors, nitroglycerin does not seem to 
effectively cross the blood brain barrier. See section, “Intraperitoneal Studies” for more 
information. A final possible reason as to why nitroglycerin is not able to cause increased 
extracellular NO• is that, despite entering the CNS properly via the aforementioned pathways, 
once nitroglycerin is oxidized, the NO• generated is rapidly inactivated by the brain’s vasculature 
as described in the section “Decay and Removal”.  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Interestingly, average AUC measured in the nucleus accumbens was, on average, 5 times 
greater than the frontal cortex. One interpretation of these results includes the notion that there is 
a higher NOS concentration in the nucleus accumbens as compared to other cortical structures 
(Vincent and Kimura, 1992). A study conducted by Vincent and Kimura selectively stained the rat 
brain for NADPH-diaphorase. This enzyme provides a specific histochemical marker for the 
production of NO•. Their results showed that the striatum exhibited some of the heaviest staining. 
Additionally, in humans, the highest levels of nNOS were measured in the nucleus accumbens, 
along with other structures such as the cerebellar cortex and septal area (Bernstein et al., 2005). 
This notion that there is a high NOS concentration in the nucleus accumbens is supported by the 
results we reported in this study. However, further research needs to be conducted within this area 
to fully elucidate the basal concentration of NOS and NO• signaling throughout the brain. 
Future Directions 
Intraperitoneal Studies 
A previous study looked into the effects of three nitric oxide donors on extracellular NO• 
concentrations in the frontal cortex and nucleus accumbens following intraperitoneal 
administration. While none of the NO• donors were found to have a significant effect, as seen in 
TABLE 4.3 and TABLE 4.4, one drug, molsidomine, showed promise as causing significant 
changes in extracellular NO• in the two subcortical areas, particularly the frontal cortex. It is an 
important consideration that these studies were conducted in awake wistar rats, as compared to 
the light sedation used in the nitroglycerin study. It is additionally interesting to note the 
differences in the average AUC for the two studies. For the frontal cortex averages for the AUC 
were ~800 for molsidomine, ~300 for nitroglycerin, ~200 for saline and ~200 for myglol-saline. 
Similar averages were found in the nucleus accumbens with the exception of myglol-saline and 
molsidomine which both had an average AUC of ~1,000. It is interesting to note that, within the 
intraperitoneal study alone, there was no large difference found between the average AUC in the 
frontal cortex as compared to the nucleus accumbens. This is an important difference between this 
study and the reported intranasal study. 
Molsidomine 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Molsidomine is a nitric oxide donor with the chemical formula of C9H14N4O4 (Aronson & 
Meyler, 2016). This compound is FDA approved to treat angina pectoris, acute myocardial 
infarction, congestive heart failure and pulmonary hypertension in oral and injectable forms 
(Rosenkranz et al., 1996). The prodrug is metabolized to SIN-1, an active metabolite, and NO 
through hydrolysis and decarboxylation in the liver and has a half-life of 1 to 2 hours. The 
bioavailability through oral administration is 44-59%. This compound, as displayed in the 
section, “Intraperitoneal Studies” is a possible candidate for intranasal administration. While the 
IP studies did not yield a significant result for Molsidomine, an increase in the concentration of 
drug administered, number of animals run through the study and potential greater uptake of the 
compound through intranasal means (as compared to systemic administration) could yield 
significant results. Furthermore, Molsidomine follows all of Lipinski’s rule of 5 with sufficiently 
low molecular weight, LogP, H bond donor atoms and H bond receptor atoms. This is interesting 
considering that nitroglycerin does not follow one of Lipinski’s rules by having too many H bond 
donor atoms. 
A large concerns with continuing intranasal research of NO• donor prodrugs include the 
rate at which the prodrug is converted to NO• in the brain parenchyma. It is quite plausible that 
the drug is converted to metabolites, SIN-1 in the case of molsidomine, and NO• prior to reaching 
the target cortical structures and therefore it can not cause a localized increase in extracellular 
NO• concentrations. Instead, the NO• is potentially rapidly inactivated by the brain’s dense 
vasculature system as NO• has been suggested to rapidly diffuse through epithelial cells to enter 
the vasculature (Santos et al., 2011). 
Intranasal Nitroglycerin 
The results of this study support nitroglycerin, without co-administration with another 
compound, as a poor candidate to continue further intranasal drug development studies. The lack 
of a significant difference, as compared to myglol, suggests that there is insufficient nitric oxide 
donated from nitroglycerin reaching the target cortical structures. As stated previously, there are 
multiple way in which this lack of increased extracellular NO• could occur. Other issues that arise 
with any intranasal drug is the lack of specificity. Distribution of nasally administered compounds  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can vary depending on the chemical properties of the drug. While a large proportion of the 
compound can remain in the olfactory region (olfactory nerve and bulb), a lack of permeability 
into deep cortical structures is not likely the cause of not statistically significant results since 
permeability into the striatum and substantia nigra has been observed for nasally administered 
DNSP-11 (Stenslik et al., 2015). A final consideration is the understood role of NO• donors in 
causing headaches and migraines. If an intranasal NO• donor was to enter stage 1 clinical, it is 
likely there would be mild to moderate side effects of headaches. This could interfere with drug 
dosage and tolerability. 
In the future, alternative NO• donor molecules, such as molsidomine, which have shown 
promise for significantly altering extracellular NO• in the nucleus accumbens and especially in 
the frontal cortex, should be considered for further investigation. I propose an identical study be 
run with an additional test agent of saline, to control for the effects of myglol, as well as 
behavioral and cognitive testing before and after drug administration to scan for behavioral 
changes in the animals that could translate to side effect profiles and tolerability in humans. 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TABLE 4.1: EXPERIMENTAL TRACING, ANIMAL 6 NG-10 
The above tracing shows the data yielded from an experiment. The graph depicts time on 
the Y axis and the change in the concentration of NO• in µM on the Y axis. This particular tracing 
is from animal 6 with the test article nitroglycerin 10mg/kg dosage. Where the two dashed lines 
intersect is the point at which nasal administration began. The tracing continues throughout the 
end of the experiment. While this example shows remarkable changes in the µM concentration of 
NO•, in total over the 5 animals, no statistically =significant result was seen. 
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TABLE 4.2: AUC OF TEST ARTICLES IN THE FRONTAL CORTEX 
Depicted above is the recorded AUC in the frontal cortex for the three treatments in this 
study: myglol, nitroglycerin 10mg/kg (NG-10) and nitroglycerin 15mg/kg (NG-15). the 15mg/kg 
dosage of nitroglycerin was the only compound to not contain the value “0” in its 95% CI. 
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TABLE 4.3: AUC OF TEST ARTICLES IN THE NUCLEUS ACCUMBENS 
Depicted above is the recorded AUC in the nucleus accumbens for the three treatments in 
this study: myglol, nitroglycerin 10mg/kg (NG-10) and nitroglycerin 15mg/kg (NG-15). None of 
the compounds elicited significant changes in extracellular nitric oxide concentrations, as seen by 






TABLE 4.4: EXTRACELLULAR NO• LEVELS IN THE FRONTAL CORTEX 
FOLLOWING INTRAPERITONEAL ADMINISTRATION OF NO• DONORS 
  Depicted above is the recorded AUC in the frontal cortex for the five treatments 
in this study: molsidomine (MD), nitroglycerin (NG), saline (S), myglol-saline (M-S) and SNP, a 
known NO• donor. None of the compounds elicited significant changes in extracellular nitric 
oxide concentrations, as seen by the 95% CI that contain the AUC value “0”. However, it is 
interesting to note how much larger the average AUC for molsidomine was as compared to the 
other NO• donors, nitroglycerin and SNP.  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TABLE 4.5: EXTRACELLULAR NO• LEVELS IN THE NUCLEUS ACCUMBENS 
FOLLOWING INTRAPERITONEAL ADMINISTRATION OF NO• DONORS 
Depicted above is the recorded AUC in the frontal cortex for the five treatments 
in this study: molsidomine (MD), nitroglycerin (NG), saline (S), myglol-saline (M-S) and SNP, a 
known NO• donor. None of the compounds elicited significant changes in extracellular nitric 
oxide concentrations, as seen by the 95% CI that contain the AUC value “0”. It is interesting to 
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